NASHUA, N.H., Sept. 11, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on…
Elraglusib is a Class-Leading GSK-3β Inhibitor with a Novel, Multimodal Mechanism of Action in Multiple Refractory Cancer TrialsOrphan Drug Designation…
Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune checkpoint inhibitorOS of…
Expanding Impact to Connect Healthcare Companies and Their Most Important Audiences PHILADELPHIA, Sept. 10, 2024 /PRNewswire/ -- Health Union, the…
CLEVELAND, Sept. 10, 2024 /PRNewswire/ -- September 4th, 2024. GenomOncology, a leading provider of precision medicine software, and Precipio, a…
Former Carevive CEO brings 25 years of experience in life sciences, healthcare technology solutions, data science, and analytics to data…
New tech-enabled services empower pharmaceutical companies to optimize biospecimen operations and data management, transforming sample data into actionable insights RICHMOND,…
Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently no fully…
New ResMed-supported research presented at ERS 2024 projects future Chronic Obstructive Pulmonary Disease (COPD) burden in Western Europe, accounting for…
BriaCell has received positive feedback from its Pre-Investigational New Drug Application (Pre-IND) meeting with FDA for Bria-PROS+™ in prostate cancerThe…